AAAAAA
Results:
1-20
|
Results: 20
Authors:
Cauley, JA
Norton, L
Lippman, ME
Eckert, S
Krueger, KA
Purdie, DW
Farrerons, J
Karasik, A
Mellstrom, D
Ng, KW
Stepan, JJ
Powles, TJ
Morrow, M
Costa, A
Silfen, SL
Walls, EL
Schmitt, H
Muchmore, DB
Jordan, VC
Citation: Ja. Cauley et al., Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial, BREAST CANC, 65(2), 2001, pp. 125-134
Authors:
Powles, TJ
Citation: Tj. Powles, Re: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study, J NAT CANC, 92(24), 2000, pp. 2040-2041
Authors:
Powles, TJ
Citation: Tj. Powles, Breast cancer prevention, BREAST CA R, 2(1), 2000, pp. 10-12
Authors:
Chang, J
Powles, TJ
Allred, DC
Ashley, SE
Makris, A
Gregory, RK
Osborne, CK
Dowsett, M
Citation: J. Chang et al., Prediction of clinical outcome from primary tamosifen by expression of biologic markers in breast cancer patients, CLIN CANC R, 6(2), 2000, pp. 616-621
Authors:
Powles, TJ
Citation: Tj. Powles, Tamoxifen for the prevention of breast cancer - Contra, EUR J CANC, 36(2), 2000, pp. 146-147
Authors:
Fallowfield, L
Fleissig, A
Edwards, R
West, A
Powles, TJ
Howell, A
Cuzick, J
Citation: L. Fallowfield et al., Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials, J CL ONCOL, 19(7), 2000, pp. 1885-1892
Authors:
Chang, J
Powles, TJ
Allred, DC
Ashley, SE
Clark, GM
Dowsett, M
Citation: J. Chang et al., Predictors of response to chemotherapy - In Reply, J CL ONCOL, 18(7), 2000, pp. 1601-1602
Authors:
Eeles, RA
Powles, TJ
Citation: Ra. Eeles et Tj. Powles, Chemoprevention options for BRCA1 and BRCA2 mutation carriers, J CL ONCOL, 18(21), 2000, pp. 93S-99S
Authors:
Gregory, RK
Powles, TJ
Salter, J
Chang, JC
Ashley, S
Dowsett, M
Citation: Rk. Gregory et al., Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy, BREAST CANC, 59(2), 2000, pp. 171-175
Authors:
Cummings, SR
Grady, D
Black, D
Eckert, S
Krueger, KA
Nickelsen, T
Glusman, JE
Powles, TJ
Cauley, JA
Norton, L
Bjarnason, NH
Morrow, M
Jordan, VC
Lippman, ME
Costa, A
Citation: Sr. Cummings et al., Estrogen-receptor status in breast cancer - Reply, J AM MED A, 283(3), 2000, pp. 338-339
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
Authors:
Chang, J
Ormerod, M
Powles, TJ
Allred, DC
Ashley, SE
Dowsett, M
Citation: J. Chang et al., Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma, CANCER, 89(11), 2000, pp. 2145-2152
Authors:
Powles, TJ
Citation: Tj. Powles, Tamoxifen for prevention of breast cancer: Report of the National SurgicalAdjuvant Breast and Bowel Project P-1 study, J NAT CANC, 91(8), 1999, pp. 730-730
Authors:
Dowsett, M
Archer, A
Assersohn, L
Gregory, RK
Ellis, PA
Salter, J
Chang, J
Mainwaring, P
Boeddinghaus, I
Johnston, SRD
Powles, TJ
Smith, IE
Citation: M. Dowsett et al., Clinical studies of apoptosis and proliferation in breast cancer, ENDOCR-R CA, 6(1), 1999, pp. 25-28
Authors:
Assersohn, L
Powles, TJ
Ashley, S
Nash, AG
Neal, AJ
Sacks, N
Chang, J
della Rovere, UQ
Naziri, N
Citation: L. Assersohn et al., Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy, ANN ONCOL, 10(12), 1999, pp. 1451-1455
Authors:
Chang, J
Powles, TJ
Allred, DC
Ashey, SE
Clark, GM
Makris, A
Assersohn, L
Gregory, RK
Osborne, CK
Dowsett, M
Citation: J. Chang et al., Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer, J CL ONCOL, 17(10), 1999, pp. 3058-3063
Authors:
Makris, A
Powles, TJ
Allred, DC
Ashley, SE
Trott, PA
Ormerod, MG
Titley, JC
Dowsett, M
Citation: A. Makris et al., Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study, BREAST CANC, 53(1), 1999, pp. 51-59
Authors:
Cummings, SR
Eckert, S
Krueger, KA
Grady, D
Powles, TJ
Cauley, JA
Norton, L
Nickelsen, T
Bjarnason, NH
Morrow, M
Lippman, ME
Black, D
Glusman, JE
Costa, A
Jordan, VC
Citation: Sr. Cummings et al., The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial, J AM MED A, 281(23), 1999, pp. 2189-2197
Authors:
Makris, A
Powles, TJ
Kakolyris, S
Dowsett, M
Ashley, SE
Harris, AL
Citation: A. Makris et al., Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma, CANCER, 85(9), 1999, pp. 1996-2000
Authors:
Leach, MO
Verrill, M
Glaholm, J
Smith, TAD
Collins, DJ
Payne, GS
Sharp, JC
Ronen, SM
McCready, VR
Powles, TJ
Smith, IE
Citation: Mo. Leach et al., Measurements of human breast cancer using magnetic resonance spectroscopy:a review of clinical measurements and a report of localized P-31 measurements of response to treatment, NMR BIOMED, 11(7), 1998, pp. 314-340
Authors:
Makris, A
Powles, TJ
Ashley, SE
Chang, J
Hickish, T
Tidy, VA
Nash, AG
Ford, HT
Citation: A. Makris et al., A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, ANN ONCOL, 9(11), 1998, pp. 1179-1184
Risultati:
1-20
|